Susquehanna Fundamental Investments, LLC I Teos Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.6 - $27.25 $333,498 - $488,592	-17,930 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$31.92 - $47.45 $37,346 - $55,516	-1,170 Reduced 6.13%	17,930 $577,000
Q4 2021 Feb 14, 2022	BUY	$26.23 - $47.86 $210,102 - $383,358	8,010 Added 72.23%	19,100 $889,000
Q3 2021 Nov 15, 2021	BUY	$23.91 - $29.58 $265,161 - $328,042	11,090 New	11,090 $299,000
Q1 2021 May 17, 2021	SELL	$30.86 - $44.2 $306,594 - $439,127	-9,935 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$21.59 - $33.95 $81,372 - $127,957	-3,769 Reduced 27.5%	9,935 $336,000
Q3 2020 Nov 16, 2020	BUY	$17.57 - $32.92 $240,779 - $451,135	13,704 New	13,704 $338,000

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.